Form 4: Akoya Biosciences Director's Stock Options Terminated Post-Quanterix Merger
Insider Transaction Report
Robert G. Shepler's stock options in Akoya Biosciences, Inc. were terminated for no consideration following the company's merger with Quanterix Corporation.
Summary
- Robert G. Shepler, a Director of Akoya Biosciences, Inc., reported the disposition of 153,731 stock options.
- The disposition occurred on July 8, 2025, coinciding with the closing of the merger between Akoya Biosciences, Inc. and Quanterix Corporation.
- Under the terms of the Amended and Restated Agreement and Plan of Merger dated April 28, 2025, all outstanding options were accelerated.
- Options with a per share exercise price equal to or greater than the Per Share Merger Consideration were automatically terminated and cancelled for no consideration.
- The terminated options included 16,860 at an exercise price of $21.95, 30,549 at $11.24, 56,322 at $5.70, and 50,000 at $2.01.
- Following these transactions, Robert G. Shepler holds 0 derivative securities in Akoya Biosciences, Inc.
- Akoya Biosciences, Inc. now operates as a wholly owned subsidiary of Quanterix Corporation.
Sentiment
Score: 3
Explanation: The sentiment is negative for the reporting person due to the termination of a significant number of stock options for no consideration, indicating a loss of potential value. While the merger itself is a strategic corporate event, this specific filing highlights a negative financial outcome for the insider's holdings.
Positives
- The completion of the merger between Akoya Biosciences, Inc. and Quanterix Corporation signifies a strategic consolidation in the life sciences sector.
- The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and compliant disposition of securities.
Negatives
- Robert G. Shepler's 153,731 stock options were terminated for no consideration, resulting in a loss of potential value for the option holder.
- The termination of these options implies that the Per Share Merger Consideration was at or below the exercise price of these specific options.
Risks
- For option holders, there is a risk that stock options may be terminated for no consideration if the merger consideration is less than or equal to the option's exercise price during a corporate acquisition.
Future Outlook
The document indicates the successful completion of the merger, with Akoya Biosciences, Inc. becoming a wholly owned subsidiary of Quanterix Corporation, signaling a consolidated future under Quanterix's strategic direction.
Industry Context
This transaction reflects a common trend of consolidation within the biotechnology and life sciences tools industry, where larger entities like Quanterix acquire specialized companies such as Akoya Biosciences to enhance their technological capabilities, expand product portfolios, and gain market share. Such mergers are often driven by the pursuit of synergies and strategic growth.
Comparison to Industry Standards
- Mergers and acquisitions are a standard strategic maneuver in the life sciences industry for companies aiming to expand their technological footprint or market presence.
- The treatment of employee and director stock options during a merger, including acceleration and termination of out-of-the-money options, is a common practice stipulated in merger agreements.
- The disposition of options for no consideration is a typical outcome for options that are 'underwater' (i.e., their exercise price is higher than the per share merger consideration) at the time of a corporate acquisition.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Robert G. Shepler | N/A | 2025-07-08 | Cessation of Section 16 reporting obligations due to Akoya Biosciences, Inc. becoming a wholly owned subsidiary of Quanterix Corporation following the merger. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Corporate Structure Change | Akoya Biosciences, Inc. merged with and into Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix Corporation, with Akoya Biosciences, Inc. surviving as a wholly owned subsidiary of Quanterix Corporation. | 2025-07-08 | This change fundamentally alters Akoya Biosciences, Inc.'s corporate governance, transitioning it from an independent public entity to a subsidiary fully integrated under Quanterix Corporation's governance framework and strategic control. |
Related Party Transactions
- The disposition of stock options by Robert G. Shepler, a Director, constitutes a transaction between a related party (insider) and the company, occurring as a direct consequence of the merger agreement between Akoya Biosciences, Inc. and Quanterix Corporation.
Stakeholder Impact
- **Shareholders (Akoya Biosciences, Inc.)**: The merger implies a cash or stock consideration for their shares, though specific details are not in this filing.
- **Option Holders (Akoya Biosciences, Inc.)**: Individuals holding out-of-the-money options, such as Robert G. Shepler, experienced the termination of their options for no consideration, resulting in a loss of potential value.
- **Employees (Akoya Biosciences, Inc.)**: Employees with similar stock options would face the same outcome. The merger also signifies integration into Quanterix's organizational structure, potentially affecting roles and reporting lines.
- **Quanterix Corporation**: Gains Akoya Biosciences, Inc. as a wholly owned subsidiary, expanding its business and technological capabilities.
Next Steps
- Akoya Biosciences, Inc. will continue operations as a wholly owned subsidiary of Quanterix Corporation.
- Robert G. Shepler is no longer subject to Section 16 reporting obligations for Akoya Biosciences, Inc. following the merger.
Key Dates
| Date | Description |
|---|---|
| 2025-04-28 | Date of the Amended and Restated Agreement and Plan of Merger. |
| 2025-07-08 | Closing Date of the merger between Akoya Biosciences, Inc. and Quanterix Corporation, and the transaction date for the disposition of stock options. |
| 2025-07-10 | Date the Form 4 was signed by Robert G. Shepler. |
| 2031-05-21 | Original expiration date of 16,860 stock options with an exercise price of $21.95, prior to their termination. |
| 2032-06-01 | Original expiration date of 30,549 stock options with an exercise price of $11.24, prior to their termination. |
| 2033-06-01 | Original expiration date of 56,322 stock options with an exercise price of $5.70, prior to their termination. |
| 2034-06-01 | Original expiration date of 50,000 stock options with an exercise price of $2.01, prior to their termination. |
Keywords
Akoya Biosciences, Quanterix Corporation, Merger, Stock Options, Form 4, Insider Transaction, Acquisition, Biotechnology, Life Sciences, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.